Keywords: NuPathe, Zelrix, Migraine, USA, FDA, CRL, Sumatriptan

NuPathe slumps as US FDA calls for more info on migraine patch Zelrix

Article | 30 August 2011

Print This

Shares in USA-based NuPathe (Nasdaq: PATH) plunged as much as 56% to $1.80 in morning trading yesterday after the company revealed that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in